Biofrontera Posts Record Q4 Revenue, Swings to Profitability
BFRI sits 58% above its 52-week low of $0.536 on light trading volume (0.1× avg).
Summary
Biofrontera Inc. reported record fourth-quarter 2025 financial results, achieving $17.1 million in revenue, a 36% year-over-year increase, and swinging to an operating income of $4.6 million from a loss in the prior year. Gross margins significantly improved to 82.4%, reflecting the benefits of the strategic transaction with Biofrontera AG and a more favorable earnout structure. This marks the company's first profitable quarter under its new cost structure, which management believes positions them for sustained profitability and cash flow breakeven in 2026. The report also included a business update, reiterating recent positive clinical trial results and FDA sNDA acceptance, some of which were previously announced on March 9th. This financial turnaround is highly material for the small-cap biopharmaceutical company, indicating a significant positive inflection point in its financial trajectory. Investors will now focus on the company's ability to sustain this growth and profitability, particularly as its clinical pipeline advances towards key regulatory milestones.
At the time of this announcement, BFRI was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1M. The 52-week trading range was $0.54 to $1.19. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.